The serum level of the morphogenetic protein fibroblast growth factor 23 (FGF-23) as a marker for the efficiency of hyperphosphatemia therapy with phosphate-binding agents in chronic kidney disease
| Autor: | N A Mukhin, Yu S Milovanov, L V Kozlovskaya, I A Dobrosmyslov, L Yu Milovanova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Терапевтический архив, Vol 88, Iss 4, Pp 41-45 (2016) |
| Druh dokumentu: | article |
| ISSN: | 0040-3660 2309-5342 |
| Popis: | Aim. To study whether the excessive production of serum fibroblast growth factor 23 (FGF-23) may be reduced with phosphate-binding agents to treat hyperphosphatemia in patients with Stage VD chronic kidney disease (CKD). Subjects and methods. The investigation enrolled 25 patients with Stage VD CKD on regular hemodialysis (HD) (12 patients with chronic glomerulonephritis, 8 with tubulointerstitial nephritis, and 5 with hypertensive nephrosclerosis); among them there were 15 men and 10 women at the age of 21 to 65 years; their mean age at inclusion in the study was 43±4.5 years. The clinical, laboratory, and instrumental examination similar to that in patients with the early stages of CKD was done. Serum FGF-23 levels (Human FGF-23 ELISA kit using monoclonal antibodies to the full FGF-23 molecule) were investigated in all the 25 patients. A whole blood sample was taken 2 days after the last session of HD before initiation of its regular procedure. Results. The elevated serum FGF-23 concentrations in the patients on regular HD correlated with their HD duration (r=0.508; p |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|